Jazz Pharmaceuticals and partner BeiGene report a 27-month median overall survival for Ziihera-based regimens in HER2+ gastroesophageal cancer, bolstering the case for label expansion.
Jazz Pharmaceuticals' Ziihera demonstrated strong long-term efficacy in the HERIZON-GEA-01 study, with nearly 40% of patients surviving at three years. This data, showing a median overall survival of 27 months when combined with chemotherapy and tislelizumab, strengthens the clinical profile of Ziihera and supports potential label expansion in HER2+ gastroesophageal adenocarcinoma.
The median overall survival observed in the study was 27 months.
No, the survival benefits were observed irrespective of PD-L1 status.
BeiGene's tislelizumab is a critical component of the combination regimen that achieved a 27-month median overall survival in the HERIZON-GEA-01 trial. The success of this combination validates the utility of tislelizumab in the HER2+ gastroesophageal adenocarcinoma treatment landscape, positioning it for broader clinical adoption.
Tislelizumab is used in combination with Ziihera and chemotherapy to treat HER2+ gastroesophageal adenocarcinoma.
Nearly 40% of patients remained alive at the three-year mark.
Jazz Pharmaceuticals announced positive long-term data from the HERIZON-GEA-01 trial, showing that Ziihera combined with tislelizumab and chemotherapy achieved a 40% survival rate at three years. The regimen delivered a median overall survival of 27 months in patients with HER2-positive gastroesophageal adenocarcinoma, regardless of PD-L1 status.
The data provides clinical validation for Ziihera's efficacy in treating HER2-positive gastroesophageal adenocarcinoma, potentially opening new revenue streams through label expansion.
Tislelizumab, developed by BeiGene, acts as a key component of the combination therapy that demonstrated statistically significant and clinically meaningful survival improvements.